Type 2 Diabetes Mellitus
Conditions
Interventions
Finerenone intervention group:Continuous application of Finerenone for at least 3 months at the Diabetes Shared Care Real World Management Follow-Up
Type 2 diabetes combined with CKD control group:CKD adjudicated at the Diabetes Shared Care Real World Management Follow-Up, but not clinically applied Finerenone
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients in the diabetes shared care management cohort of Peking University First Hospital who completed the initial registration from October 2016 to February 2024 2. Patients with type 2 diabetes; 3. Aged >18 years; 4. Patients with a clinical diagnosis of diabetic nephropathy and UACR =30mg/g
Exclusion criteria
Exclusion criteria: 1. Patients who, as of February 2024, have been withdrawn from follow-up in the diabetes shared care outpatient management cohort for various reasons; 2. Patients with non-type 2 diabetes such as pre-diabetes, type 1 diabetes, and specific types of diabetes 3. Patients with a clinical or renal puncture diagnosis of non-diabetic nephropathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of Urinary microalbumin creatinine ratio from baseline at 3-6 months of Finerenone treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of Estimated glomerular filtration rate and Serum potassium from baseline at 3-6 months of Finerenone treatment;Change of Urinary microalbumin creatinine ratio, Estimated glomerular filtration rate and Serum potassium from baseline at 3-6 months of Finerenone treatment combine/or SGLT-2i treatment;Change of Urinary microalbumin creatinine ratio, Estimated glomerular filtration rate and Serum potassium from baseline at 3-6 months of Finerenone treatment in Patients with different proteinuria levels;Change of Urinary microalbumin creatinine ratio, Estimated glomerular filtration rate and Serum potassium from baseline at 3-6 months of Finerenone treatment in Patients with different CKD duration; | — |
Countries
China
Contacts
Public ContactLi Ang
Peking University First Hospital
Outcome results
None listed